- Our Products & Expertise
- About Baxter
- Corporate Responsibility
- Contact & Support
A global leader in multi-organ support therapy options, Baxter has been at the forefront of advancing new technologies and revolutionizing treatment for critically ill patients.
Every day, our comprehensive portfolio of multi-organ therapies help treat critically ill, hospitalized patients in intensive care units around the world. Our Acute Therapies portfolio has products designed to deliver a complete range of extracorporeal (outside the body) blood purification (EBP) therapies to treat acute kidney injury, acute respiratory distress syndrome and other conditions, including our leading PRISMAFLEX system. PRISMAFLEX gives clinicians the ability to meet patients’ diverse needs and is used in more hospitals worldwide than any other EBP system.
Acute kidney injury (AKI) is a sudden decrease in kidney function over a period of hours to days, often the result of illness, trauma or infection. The sudden loss of kidney function leads to the accumulation of toxins and fluid in the body that, if left untreated, may lead to death. In the U.S. alone, AKI is estimated to impact nearly 4 million patients each year.
Continuous renal replacement therapy (CRRT) is used to treat the most severe form of AKI. During CRRT, waste products in the blood are cleared, and the cleaned blood is returned to the body.
The PRISMAFLEX System is a flexible, filter-based solution that meets the demands of multiple therapies with a versatile platform that can be customized to specific patient needs.LEARN MORE